We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Alexion Recalls More Soliris Due to Persistent Particle Problem

Alexion Recalls More Soliris Due to Persistent Particle Problem

June 6, 2014

Alexion is pulling more of its flagship product Soliris from the market due to visible particles that arose from a manufacturing problem, its third recall in less than a year.

The drugmaker voluntarily recalled nine lots of the rare blood disease drug after visible protein particles were discovered in a single lot during periodic stability testing, the company said.

The move follows a voluntary recall announced in November 2013 and another in August 2013 due to a similar particulate problem. While the particles were discovered in one lot, Alexion is recalling the other eight because they were made using the same process component during vial filling that was the culprit of earlier recalls, the company said.

“Alexion believes it has identified the process component that result in the presence of the visible particles and implemented a change to the process,” it noted.

The drugmaker declined to elaborate on specifics, but noted the problems were tied to a third-party contractor, one of three used by the drugmaker. “We replaced the single process step with this one third-party vial filler,” Alexion spokeswoman Kim Diamond said.

Alexion hasn’t received any adverse safety reports from the product. But it stressed that particulate in a parenteral drug could block the flow of blood in vessels, which could lead to life-threatening blood clots. The particulates also could create an immune reaction.

The company said it doesn’t anticipate any supply disruptions due to the recall. The drug, which is Alexion’s only approved product, treats the rare blood disease paroxysmal nocturnal hemoglobinuria and genetic disease atypical hemolytic uremic syndrome, Diamond said the company expects that the current and prior Soliris recalls will cost the company between $10 and $25 million.

Don’t let this happen to you, prevent contamination by purchasing Manufacturing Sterile Products to Meet EU and FDA Guidelines.

Pharmaceuticals Quality GMPs Commercial Operations

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

  • FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy

  • FDA Expands Approval for Merck’s Keytruda in NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing